NCT02529059 - SSAT058: Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions

HIV

Interventions

DRUG

Eviplera

A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.

Trial Locations (3)

Brighton & Sussex University Hospitals Nhs Trust, Brighton

St. Mary's Hospital, London

St. Stephen's Centre, London